|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Navigating evolving regulatory frameworks across markets
|
|
Wednesday, 06 May, 2026, 16 : 00 PM [IST]
|
|
Alka Chauhan & Dr Jasvir Singh
|
The nutraceutical industry has emerged as one of the fastest-growing sectors within global healthcare, driven by rising consumer demand for preventive wellness, functional nutrition, and self-care solutions. However, as market opportunities expand, so do regulatory complexities. Unlike conventional foods or pharmaceuticals, nutraceuticals occupy a unique and often contested space between nutrition and medicine. This has led to significant differences in classification, approval pathways, permissible claims, and compliance expectations across jurisdictions.
This paper examines the evolving regulatory frameworks governing nutraceuticals in major markets including United States, European Union, United Kingdom, Canada, Australia, and India. It explores the persistent challenge of determining whether products should be regulated as foods, supplements, or therapeutic goods, and highlights the growing global emphasis on scientific substantiation, labelling accuracy, and responsible marketing. The analysis underscores the need for companies to adopt region-specific strategies while maintaining scientific credibility and regulatory agility in an increasingly scrutinised marketplace.
Introduction
The term nutraceutical blends the concepts of nutrition and pharmaceutical, reflecting products designed to offer health benefits beyond basic nutrition. These may include vitamins, minerals, probiotics, botanical extracts, functional beverages, fortified foods, and specialty supplements intended to support immunity, metabolism, digestion, cognition, cardiovascular health, or general wellness.
Over the past decade, the nutraceutical market has transformed from a niche wellness segment into a mainstream global industry. Consumers are increasingly seeking preventive healthcare options, particularly in response to lifestyle disorders, aging populations, rising healthcare costs, and greater health awareness following the Covid-19 era.
Yet despite commercial momentum, the regulatory identity of nutraceuticals remains fragmented. Unlike prescription drugs, these products are not uniformly evaluated under a single global standard. Instead, they are regulated under varying food, supplement, or therapeutic frameworks depending on geography, composition, claims, and intended use.
For manufacturers, marketers, and regulatory professionals, success in this sector requires more than product innovation. It demands a sophisticated understanding of global compliance systems, scientific evidence requirements, and the legal nuances that determine market access.
The Core Regulatory Paradox: Food or Drug?
At the centre of nutraceutical regulation lies a persistent dilemma: When does a health-supporting product remain a food, and when does it become a drug?
Most jurisdictions begin by treating nutraceuticals as foods or dietary supplements. However, the moment a product claims to diagnose, cure, mitigate, prevent, or treat disease, it may shift into pharmaceutical or therapeutic territory.
For example:
- A calcium supplement supporting bone health may remain a food supplement.
- A product claiming to reverse osteoporosis may be treated as a drug.
- A probiotic promoting digestive balance may qualify as food.
- A probiotic claiming to treat ulcerative colitis may require medicinal authorisation.
This distinction is critical because drug classification often triggers significantly stricter requirements including clinical evidence, pre-market approval, pharmacovigilance, and manufacturing controls. As a result, wording, claims strategy, and evidence generation are central to regulatory success.
United States: Market-Driven but Closely Watched
The United States remains one of the largest nutraceutical markets globally. Dietary supplements are primarily governed by the Dietary Supplement Health and Education Act (DSHEA), 1994.
Under DSHEA:
- Supplements are regulated more like foods than drugs.
- Manufacturers are responsible for ensuring safety before marketing.
- Pre-market approval is generally not required for most products.
- The FDA monitors products post-market for safety, misbranding, or adulteration.
- New Dietary Ingredients may require notification.
Claims fall into specific categories such as:
- Structure/function claims (“supports immune health”)
- Nutrient deficiency claims
- General wellness statements
However, disease treatment claims are prohibited without drug approval.
The Federal Trade Commission (FTC) also plays a major role by regulating advertising practices and requiring claims to be truthful, non-misleading, and evidence-based. The U.S. model offers speed to market but also places substantial responsibility on industry players.
European Union: Science First Regulation
The European Union applies one of the world’s most stringent evidence-based approaches. Food supplements are regulated under Directive 2002/46/EC, while health claims are governed through the Nutrition and Health Claims Regulation.
The European Food Safety Authority (EFSA) evaluates health claims using rigorous scientific criteria. Only approved claims supported by strong evidence may be used.
This has led to:
- High rejection rates for weak or vague claims
- Stronger consumer protection
- Greater demand for human clinical data
- More disciplined product positioning
For companies, the EU rewards robust science but can be resource-intensive for innovation pipelines.
United Kingdom: Independent but Familiar
Post-Brexit, the United Kingdom now operates independently through national authorities such as the Food Standards Agency (FSA) and related enforcement bodies.
While many EU-origin principles still influence UK practice, divergence is gradually increasing in:
- Administrative pathways
- Labelling adjustments
- National guidance interpretation
- Claims management processes
For multinational businesses, the UK increasingly requires dedicated regulatory planning rather than assuming automatic EU alignment.
Canada
Canada regulates many nutraceutical products as Natural Health Products (NHPs). Products typically require licensing before sale and are assigned a Natural Product Number (NPN).
Applications may involve:
- Ingredient review
- Safety evidence
- Recommended use validation
- Label assessment
This creates a more structured pre-market control model.
Australia
Australia distinguishes products based on risk and intended use under the Therapeutic Goods Administration (TGA).
Products may be:
- Listed (lower risk)
- Registered (higher risk)
Australia is known for strong quality expectations, manufacturing standards, and post-market surveillance.
Codex Alimentarius: Global Reference Point
Though not a direct regulator, Codex Alimentarius, developed by FAO and WHO, plays a vital role in international harmonisation.
Codex frameworks influence:
- Vitamin and mineral reference values
- Labelling principles
- Nutrition claims norms
- Food safety expectations
Many national authorities reference Codex standards when designing domestic regulations or resolving trade disputes.
India: Rapid Growth with Structured Evolution
India’s nutraceutical sector has expanded rapidly, supported by preventive health awareness, traditional wellness heritage, and increasing modern retail access.
Products are regulated under the Food Safety and Standards Authority of India (FSSAI), particularly through frameworks covering health supplements, nutraceuticals, foods for special dietary use, and related categories.
India’s model combines: - Defined ingredient permissions
- Labelling controls
- Claim limitations
- Product category clarity
- Growing emphasis on scientific substantiation
The Indian market is particularly dynamic because it blends modern nutrition science with strong consumer familiarity toward botanicals, Ayurveda-linked ingredients, and wellness traditions. As enforcement matures, companies increasingly need disciplined dossiers, compliant communication, and stronger technical justification.
Strategic Implications for Industry
Across markets, several clear trends are emerging:
- Science is replacing marketing hype Unsupported claims face increasing scrutiny.
- Labels are becoming legal documents Small wording changes can alter regulatory classification.
- Quality systems matter more than ever GMP, traceability, and contamination control are central.
- One formula cannot fit all markets Global brands require localised regulatory adaptation.
- Regulatory intelligence is a competitive advantage
Fast-moving firms that anticipate changes outperform reactive players.
The global nutraceutical landscape is no longer a lightly regulated wellness frontier. It is becoming a sophisticated, evidence-driven sector where compliance, scientific credibility, and strategic positioning determine commercial success. While the core challenge of food versus drug remains unresolved across jurisdictions, one direction is clear: regulators increasingly expect transparency, substantiation, and consumer protection.
For organisations seeking long-term growth, regulatory strategy must evolve from a back-end approval function into a front-end business capability integrated with innovation, branding, and market expansion.
In the nutraceutical world, science opens the door—but regulation decides who enters.
(Chauhan is from Amway India Limited, Gurgaon, and Singh belongs to Danisco India Pvt Limited (wholly-owned subsidiary of IFF), Gurgaon)
|
|
|
|
|
|
|
|
|
|